Rigel Pharmaceuticals, Inc.
(NASDAQ : RIGL)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
TSROTESARO, Inc.
-1.07%73.6914.4%$580.10m
AMGNAmgen Inc.
-2.76%192.071.2%$565.07m
GILDGilead Sciences, Inc.
-2.64%65.570.9%$530.36m
CELGCelgene Corporation
-2.21%68.201.2%$520.26m
BIIBBiogen Inc.
-1.75%314.551.3%$359.40m
ILMNIllumina, Inc.
-2.44%326.463.5%$350.15m
REGNRegeneron Pharmaceuticals, Inc.
0.70%381.172.6%$273.12m
VRTXVertex Pharmaceuticals Incorporated
-1.94%170.061.9%$226.47m
AAgilent Technologies, Inc.
-2.49%69.371.5%$225.54m
ALXNAlexion Pharmaceuticals, Inc.
-2.67%109.432.0%$146.61m
INCYIncyte Corporation
-1.55%66.252.5%$97.76m
EXASExact Sciences Corporation
0.68%68.3125.3%$93.39m
SRPTSarepta Therapeutics, Inc.
-2.05%119.5215.4%$90.77m
NKTRNektar Therapeutics
-3.92%36.515.5%$84.08m
SGENSeattle Genetics, Inc.
-0.85%60.486.6%$81.91m

Company Profile

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. It focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Its current product development programs include Fostamatinib Oral SYK Inhibitor and R348 Topical Ophthalmic JAK/SYK Inhibitor. The company was founded by Donald G. Payan, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.